Clinical application of inhibitors of fibrinolysis.
The basic proteinase inhibitor from bovine organs, aprotinin, was first identified in 1930 and its effect on enzyme and other biological systems has since been extensively studied. Aprotinin can only be administered intravenously and has a half-life of about 2 hours. Its administration at the start of cardiopulmonary bypass surgery appears to reduce blood loss and to protect against global myocardial ischaemia. Similarly, a smaller infarct size seems to result from early administration of aprotinin within the first hour after myocardial infarction, though further studies are needed to confirm this effect. A combination of aprotinin with tranexamic acid may be effective in preventing or delaying rebleeding after rupture of an intracerebral aneurysm; the addition of aprotinin seems to decrease the incidence of delayed cerebral vasospasm and ischaemic complications which are sometimes noted when tranexamic acid alone is used. Aprotinin is also effective as adjuvant treatment in traumatic haemorrhagic shock. The recommended loading dose is 15,000 to 20,000 KIU/kg bodyweight administered as a short intravenous infusion, followed by 50,000 KIU/hour by continuous infusion. Side effects of aprotinin are very rare. Epsilon-Aminocaproic acid (EACA), p-aminomethylbenzoic acid (PAMBA) and tranexamic acid are synthetic antifibrinolytic amino acids. Saturation of the lysine binding sites of plasminogen with these inhibitors displaces plasminogen from the fibrin surface. On a molar basis tranexamic acid is at least 7 times more potent that epsilon-aminocaproic acid and twice as potent as p-aminomethylbenzoic acid. All 3 compounds are readily absorbed from the gastrointestinal tract and excreted in active form in the urine. The plasma half-life of tranexamic acid is about 80 minutes. The main indications for tranexamic acid are the prevention of excessive bleeding after tonsillectomy, prostatic surgery, and cervical conisation, and primary and IUD-induced menorrhagia. It is possible that gastric and intestinal bleeding can also be reduced as well as recurrent epistaxis. Tranexamic acid could also be useful after ocular trauma. The value of fibrinolysis inhibitors in the prevention of bleeding after tooth extraction in patients with haemophilia is well documented, as is the treatment of hereditary angioneurotic oedema. The usual dose of tranexamic acid is 0.5 to 1g (10 to 15 mg/kg bodyweight) given intravenously 2 to 3 times daily, or 1 to 1.5 g orally 3 to 4 times daily. This dose needs to be reduced in patients with renal insufficiency. The main side effects of tranexamic acid are nausea or diarrhoea.
Verstraete
M
M
D010129:4-Aminobenzoic Acid / Q000627:therapeutic use; D015119:Aminocaproic Acid / Q000494:pharmacology; D000799:Angioedema / Q000188:drug therapy; D000933:Antifibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007611:Aprotinin / Q000008:administration & dosage / Q000009:adverse effects / Q000032:analysis / Q000494:pharmacology / Q000627:therapeutic use; D001793:Blood Preservation; D003316:Corneal Diseases / Q000188:drug therapy; D004347:Drug Interactions; D004844:Epistaxis / Q000188:drug therapy; D005260:Female; D006467:Hemophilia A / Q000188:drug therapy; D006470:Hemorrhage / Q000188:drug therapy; D006801:Humans; D007434:Intrauterine Devices / Q000009:adverse effects; D007700:Kinetics; D008297:Male; D009203:Myocardial Infarction / Q000188:drug therapy; D010051:Ovarian Neoplasms / Q000188:drug therapy; D010195:Pancreatitis / Q000188:drug therapy; D011183:Postoperative Complications; D012769:Shock / Q000188:drug therapy; D013924:Thrombophlebitis / Q000188:drug therapy; D014148:Tranexamic Acid / Q000009:adverse effects / Q000627:therapeutic use; D014361:Trypsin Inhibitors; D062366:para-Aminobenzoates
D000933:Antifibrinolytic Agents; D014361:Trypsin Inhibitors; D062366:para-Aminobenzoates; C015668:4-aminomethylbenzoic acid; D014148:Tranexamic Acid; D007611:Aprotinin; D010129:4-Aminobenzoic Acid; D015119:Aminocaproic Acid